You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Laurus Labs Q2 PAT slides 17% YoY to Rs 202 cr

Capital Market 

The pharma company's consolidated net profit fell 16.66% to Rs 201.90 crore on 5.68% increase in net sales to Rs 1203.48 crore in Q2 September 2021 over Q2 September 2020.

Profit before tax (PBT) fell 16.46% to Rs 262.59 crore in Q2 September 2021 over Q2 September 2020.

During the quarter, EBITDA fell 8% to Rs 348 crore while EBITDA margins stood at 29%.

Revenue growth is driven by sustained performance in Finished Dosage Forms (FDF), synthesis and sequential recovery in other APIs while ARVs APIs declined.

FDF business recorded a growth of 10% YoY to Rs 495 crore (41% of total revenues vs 40% last year). API business reported de-growth for the quarter at 8% YoY to Rs 527 crore.

The synthesis division delivered growth of 34% YoY in Q2 to Rs 155 crore. The bio division clocked sales of Rs 26 crore as new capacity begin to contribute.

Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said; While our Q2 results are slightly subdued we achieved healthy momentum for overall H1 FY22. Laurus Labs reported a modest revenue growth of 6% at ₹1,203 crs in Q2FY22, due to transient impact of channel de-stocking for ARV business. EBITDA has declined by 8% to ₹348 crs while our EBITDA margins were maintained. In the 1HFY22, our Revenues have grown 17% to ₹2,482crs, driven by strong momentum in FDF and CDMO business. EBITDA has grown by 13 % to ₹748 crs and our Margins have sustained over 30%. Our growth accelerators remains on tracksupported by much needed strategic investments.

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs.

Ahead of the result announcement, Laurus Labs fell 6.66% to Rs 536.65.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, October 28 2021. 16:17 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU